Eytan Stein
Chief, Leukemia Service · New York Presbyterian Hospital
Credentials: · · · · · ·
History
PresentLeukemia Service Division · New York Presbyterian Hospital
- 2003–2007
Research
Blood · 2022 · 2,814 citations
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
New England Journal of Medicine · 2018 · 1,234 citations
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Blood · 2017 · First of 27 authors · 1,232 citations
- MT
57 papers
41 papers
28 papers
- AG
27 papers
27 papers
21 papers
21 papers
20 papers
Grants
- 2019–2032
Network Lead Academic Participating Site: Memorial Sloan Kettering Cancer Center
National Cancer Institute · UG1
PI · $1.1M · Sloan-Kettering Inst Can Research
- 2021–2031
The Memorial Sloan Kettering Cancer Center SPORE in Leukemia
National Cancer Institute · P50
PI · $9.3M · Sloan-Kettering Inst Can Research
Clinical trials
- 2026–2028
A Study of CRD3874-SI in People With Leukemia
Principal investigator · Recruiting · Phase 1
Memorial Sloan Kettering Cancer Center
- 2025–2027
A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)
Principal investigator · Recruiting · Phase 2
Memorial Sloan Kettering Cancer Center
- 2023–2027
Principal investigator · Recruiting · Phase 1
Memorial Sloan Kettering Cancer Center
- 2021–2026
A Study of Enasidenib in People With Clonal Cytopenia of Undetermined Significance
Principal investigator · Completed · Phase 1
Memorial Sloan Kettering Cancer Center